A Delaware judge threw out a 2017 decision that had Teva on the hook for more than $235 million over its generic for GlaxoSmithKline’s chronic heart failure and blood pressure drug Coreg (carvedilol).

In a decision last June, a federal jury in Delaware found Teva infringed on GSK’s patent for the drug and awarded GSK $234.1 million for lost profits and an additional $1.4 million in royalties.

The FDA approved Teva’s generic in 2004 as a conditional “carve-out” approval, with GSK retaining exclusive rights to market the drug for chronic heart failure. GSK sued when Teva added that indication to its generic’s labeling in 2011.